Pharmacy Times
AUGUST 10, 2024
Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.
STAT
AUGUST 10, 2024
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
AUGUST 10, 2024
The commencement of the phase 1 clinical trial of SAT-3247 is expected in Q3 of 2024.
Drug Topics
AUGUST 10, 2024
Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The Honest Apothecary
AUGUST 10, 2024
“Yep, son, we have met the enemy, and he is us.” – Walt Kelly The line above comes from “Pogo”, the humble and contemplative opossum from Walt Kelly’s long-running mid-20th century comic strip. Here, Pogo is expressing his acknowledgement and disappointment that from an environmental perspective, we are actually the enemy.
Drug Topics
AUGUST 10, 2024
Check out this recap of articles published on our sister sites during the past week.
BioPharm
AUGUST 10, 2024
AAV and lentivirus both have pros and cons in their use for specific gene therapy applications.
Expert insights. Personalized for you.
153 
Let's personalize your content